Autologous hematopoietic stem cell transplantation + BCMA CAR-T + GPRC5D/CD3 BiTEs for bites and stings

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 6 Aug 2025: Trial registered, NCT07106684
  2. 9 Aug 2025: Trial started, NCT07106684

The trials

NCT07106684: ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia

State
Under way
Phase
Phase 2
People
20 planned
Started
9 Aug 2025
Primary completion
1 Aug 2027
Arms
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance
Results
None posted
  1. 6 Aug 2025: Trial registered
  2. 9 Aug 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.